{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T09:58:42Z","timestamp":1780912722333,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P1-0208"],"award-info":[{"award-number":["P1-0208"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J1-4417"],"award-info":[{"award-number":["J1-4417"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118360","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:58:28Z","timestamp":1762765108000},"page":"118360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Synthesis and structure-activity relationship study of novel quinazolin-4(3H)-one derivatives as Toll-like receptor 7 and 8 agonists with immunomodulatory activity"],"prefix":"10.1016","volume":"302","author":[{"given":"Nika","family":"Stra\u0161ek Benedik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Luki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tja\u0161a","family":"Slokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Dol\u0161ak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"\u0160vajger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Kranjc Brezar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerij","family":"Talagayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Wolber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"\u010cema\u017ear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidor","family":"Sosi\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-3450","authenticated-orcid":false,"given":"Matej","family":"Sova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118360_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048875","article-title":"Isolated toll-like receptor transmembrane domains are capable of oligomerization","volume":"7","author":"Godfroy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118360_bib2","doi-asserted-by":"crossref","first-page":"756315","DOI":"10.3389\/fcell.2021.756315","article-title":"Toll-like receptors as a therapeutic target in the era of immunotherapies","volume":"9","author":"Farooq","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.118360_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-022-00436-7","article-title":"Targeting toll-like receptor 7\/8 for immunotherapy: recent advances and prospectives","volume":"10","author":"Sun","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ejmech.2025.118360_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118360_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112238","article-title":"Agonist and antagonist ligands of toll-like receptors 7 and 8: ingenious tools for therapeutic purposes","volume":"193","author":"Patinote","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib6","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1021\/acs.jmedchem.2c01655","article-title":"Small-molecule modulators targeting toll-like receptors for potential anticancer therapeutics","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.05.013","article-title":"Evolution of toll-like receptor 7\/8 agonist therapeutics and their delivery approaches: from antiviral formulations to vaccine adjuvants","volume":"175","author":"Bhagchandani","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2025.118360_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128548","article-title":"Toll-like receptor 7 and 8 imidazoquinoline-based agonist\/antagonist pairs","volume":"59","author":"Yang","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118360_bib9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/acsmedchemlett.7b00256","article-title":"Design and synthesis of N1-Modified imidazoquinoline agonists for selective activation of toll-like receptors 7 and 8","volume":"8","author":"Larson","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118360_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1021\/ml300079e","article-title":"Discovery of imidazoquinolines with toll-like receptor 7\/8 independent cytokine induction","volume":"3","author":"Shi","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118360_bib11","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm100358c","article-title":"Structure\u2212Activity relationships in human toll-like receptor 7-Active imidazoquinoline analogues","volume":"53","author":"Shukla","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib12","first-page":"1","article-title":"A review of topical imiquimod in the management of basal cell carcinoma, actinic keratoses, and other skin lesions","author":"Ryu","year":"2009","journal-title":"Clin. Med. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118360_bib13","doi-asserted-by":"crossref","first-page":"7324","DOI":"10.1021\/jm400815m","article-title":"Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis","volume":"56","author":"Roethle","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib14","author":"Shikuan"},{"key":"10.1016\/j.ejmech.2025.118360_bib15","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1021\/acs.jmedchem.6b01860","article-title":"Identification of high-potency human TLR8 and dual TLR7\/TLR8 agonists in Pyrimidine-2,4-diamines","volume":"60","author":"Beesu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/13543776.2020.1825687","article-title":"Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 \u2013 2020","volume":"30","author":"Kieffer","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2025.118360_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104495","article-title":"Structure-guided approaches to modulate endosomal toll-like receptors TLR7, TLR8 and TLR9: advances, challenges and therapeutic promise","volume":"30","author":"Matziol","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118360_bib18","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1021\/acs.jmedchem.1c00300","article-title":"Structural evolution and translational potential for agonists and antagonists of endosomal toll-like receptors","volume":"64","author":"Talukdar","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1796002","article-title":"Trial watch: experimental TLR7\/TLR8 agonists for oncological indications","volume":"9","author":"Frega","year":"2020","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejmech.2025.118360_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104851","article-title":"In silico methods and tools for drug discovery","volume":"137","author":"Shaker","year":"2021","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118360_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nri2301","article-title":"TLR4 signalling","volume":"8","author":"Bell","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.118360_bib22","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1016\/j.celrep.2018.11.081","article-title":"Structural analyses of toll-like receptor 7 reveal detailed RNA sequence specificity and recognition mechanism of agonistic ligands","volume":"25","author":"Zhang","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118360_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1021\/acsmedchemlett.4c00463","article-title":"Structure-based design of novel TLR7\/8 agonist payloads enabling an immunomodulatory conjugate approach","volume":"16","author":"Poudel","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118360_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012165","article-title":"New insights into the role of IFN-\u03b1\/\u03b2 and TLR7\/8\/9 in cancer immunotherapy and systemic autoimmunity","volume":"13","author":"Krieg","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2025.118360_bib25","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1073\/pnas.211423598","article-title":"TNF-\u03b1-dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection","volume":"98","author":"Trevejo","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2025.118360_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656908","article-title":"The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment","volume":"12","author":"Laha","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118360_bib27","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Kawai","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2025.118360_bib28","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.4049\/jimmunol.162.4.2044","article-title":"Human effector memory T cells express CD86: a functional role in naive T cell priming","volume":"162","author":"Jeannin","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118360_bib29","article-title":"Immunologic significance of CD80\/CD86 or major histocompatibility Complex-II expression in thymic epithelial tumors","volume":"4","author":"Ikeda","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.ejmech.2025.118360_bib30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2025.118360_bib31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2025.118360_bib32","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.xphs.2017.04.041","article-title":"Thermosensitive gel\u2013based formulation for intratumoral delivery of toll-like receptor 7\/8 dual agonist, MEDI9197","volume":"106","author":"Fakhari","year":"2017","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118360_bib33","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.1021\/jm5007935","article-title":"Rational use of plasma protein and tissue binding data in drug design","volume":"57","author":"Liu","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib34","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1078-0432.CCR-11-1625","article-title":"VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC","volume":"18","author":"Lu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118360_bib35","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1021\/acs.jmedchem.5b01087","article-title":"Structure-based design of human TLR8-Specific agonists with augmented potency and adjuvanticity","volume":"58","author":"Beesu","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib36","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1021\/acs.jcim.5b00136","article-title":"LiSiCA: a software for ligand-based virtual screening and its application for the discovery of butyrylcholinesterase inhibitors","volume":"55","author":"Le\u0161nik","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118360_bib37","author":"Kaneko"},{"key":"10.1016\/j.ejmech.2025.118360_bib38","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1021\/acs.jmedchem.6b00039","article-title":"Optimization of a novel quinazolinone-based series of transient receptor potential A1 (TRPA1) antagonists demonstrating potent in vivo activity","volume":"59","author":"Schenkel","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib39","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1016\/S0040-4020(01)80968-6","article-title":"New methods and reagents in organic synthesis. 92. A stereoselective synthesis of tilivalline and its analogs","volume":"47","author":"Mori","year":"1991","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2025.118360_bib40","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12917-020-02451-y","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"16","author":"Percie du Sert","year":"2020","journal-title":"BMC Vet. Res."},{"key":"10.1016\/j.ejmech.2025.118360_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0023677217724823","article-title":"PREPARE: guidelines for planning animal research and testing","volume":"52","author":"Smith","year":"2018","journal-title":"Lab. Anim."},{"key":"10.1016\/j.ejmech.2025.118360_bib42","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41596-024-00998-w","article-title":"OBSERVE: guidelines for the refinement of rodent cancer models","volume":"19","author":"De Vleeschauwer","year":"2024","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2025.118360_bib43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2342-12-12","article-title":"Tumour size measurement in a mouse model using high resolution MRI","volume":"12","author":"Montelius","year":"2012","journal-title":"BMC Med. Imag."},{"key":"10.1016\/j.ejmech.2025.118360_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118360_bib45","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nmeth.1455","article-title":"Coding of facial expressions of pain in the laboratory mouse","volume":"7","author":"Langford","year":"2010","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejmech.2025.118360_bib46","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2025.118360_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2025.118360_bib48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/prot.22234","article-title":"Protonate3D: assignment of ionization states and hydrogen coordinates to macromolecular structures","volume":"75","author":"Labute","year":"2009","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.ejmech.2025.118360_bib49","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1006\/jmbi.1996.0897","article-title":"Development and validation of a genetic algorithm for flexible docking1","volume":"267","author":"Jones","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118360_bib50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced protein\u2212ligand docking with plants","volume":"49","author":"Korb","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118360_bib51","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X","article-title":"MMFF VI. MMFF94s option for energy minimization studies","volume":"20","author":"Halgren","year":"1999","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118360_bib52","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J. Chem. Inf. Model."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:59:46Z","timestamp":1780909186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S0223523425011250"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118360","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and structure-activity relationship study of novel quinazolin-4(3H)-one derivatives as Toll-like receptor 7 and 8 agonists with immunomodulatory activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118360"}}